James N. Woody

Infirmerie Protestante — France

Immunology and Microbiology · Life Sciences

30h-index8.1kcitations108works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

T-cell and B-cell Immunology(27), Immune Cell Function and Interaction(23), Monoclonal and Polyclonal Antibodies Research(15), Immunotherapy and Immune Responses(9), Rheumatoid Arthritis Research and Therapies(8)

Publications107 total

La foi et ses raisons…
Karthala eBooks·2022
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
The Lancet·2020· 550 citedOpen Access
A PHASE 1B/2 STUDY OF ORAL NANATINOSTAT (N) AND VALGANCICLOVIR (VG) IN SUBJECTS WITH EPSTEIN‐BARR VIRUS (EBV)‐ASSOCIATED LYMPHOMAS
Hematological Oncology·2019· 1 cited
Epigenetic regulation of immunotherapy and T cell exhaustion by tractinostat in a syngeneic CT26 colon cancer mouse model.
Journal of Clinical Oncology·2018
The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis
Best Practice & Research Clinical Rheumatology·2004· 77 cited
Plummer & Vinson of the Plummer-Vinson syndrome
1999
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
Arthritis & Rheumatism·1998· 1.6k cited
Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2)
Lara D. Veeken·1997· 57 citedOpen Access
Treatment with a Chimeric CD4 Monoclonal Antibody is Associated with a Relative Loss of CD4+/CD45RA+Cells in Patients with Rheumatoid Arthritis
Journal of Autoimmunity·1997· 20 cited
Inhibition of Immunoreactive Tumor Necrosis Factor-  by a Chimeric Antibody in Patients Infected with Human Immunodeficiency Virus Type 1
The Journal of Infectious Diseases·1996· 68 cited
Deactivation of vascular endothelium by monoclonal anti–tumor necrosis factor α antibody in rheumatoid arthritis
Arthritis & Rheumatism·1996· 238 citedOpen Access
Percentage of anti‐CD4 monoclonal antibody‐coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens
Arthritis & Rheumatism·1996· 68 cited
Double‐blind, placebo‐controlled multicenter trial using chimeric monoclonal anti‐cd4 antibody, cm‐t412, in rheumatoid arthritis patients receiving concomitant methotrexate
Arthritis & Rheumatism·1995· 109 cited
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
Gastroenterology·1995· 1.1k cited
Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
The Lancet·1994· 643 cited
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
Arthritis & Rheumatism·1993· 1.0k cited
The Navy Forward Laboratory during Operations Desert Shield/Desert Storm
Military Medicine·1993· 11 cited
Respiratory disease among military personnel in Saudi Arabia during Operation Desert Shield.
American Journal of Public Health·1993· 67 cited
T-cell-targeted immunotherapy
Immunology Today·1992· 18 cited
Diarrheal Disease during Operation Desert Shield
New England Journal of Medicine·1991· 254 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Marc Feldmann(12), Kenneth C. Hyams(10), Jonathan R. Lamb(8), David D. Eckels(7), Phil Lake(7), Ravinder N. Maini(6), Michael J. Elliott(5), A. Long-Fox(3), Robert J. Hartzman(3), Aftab Ahmed(3), James P. Burans(3), John C. Morrill(3), Peter C. L. Beverley(3), P. Charles(2), Fionula M. Brennan(2), J. A. Bijl(2), B R Merrell(2), Patrick J. Rozmajzl(2), Nicola Green(2), Armead H. Johnson(2)